Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study is to assess the tolerability of bifeprunox with the progressive elimination of
titration steps to achieve the shortest tolerated titration dosing to a dose of 40 mg/day in
either schizophrenia or bipolar disorder subjects. Study duration is 2 months with an
optional open-label 26-week extension study.
Phase:
Phase 2
Details
Lead Sponsor:
Solvay Pharmaceuticals
Collaborators:
H. Lundbeck A/S Wyeth is now a wholly owned subsidiary of Pfizer